用talquetamab治疗复发/逆转多发性髓瘤患者的临床管理
Ajai Chari1, Amrita Krishnan2, Leo Rasche3
1Department of Medicine, Hematology, and Medical Oncology and Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY.
Clinical lymphoma, myeloma & leukemia
|June 13, 2024
概括
塔尔基塔马布是复发性/耐药性多发性髓瘤 (RRMM) 的双特异性抗体,具有可控的副作用,主要是皮肤和口腔毒性. 管理策略确保患者的生活质量和治疗坚持.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 临床试验 临床试验
背景情况:
- 塔尔克塔马布是一种新型双特异性抗体,向多发性髓瘤中G蛋白结合受体家族C组5成员D (GPRC5D).
- 在MonumenTAL-1试验中,对三级暴露复发性/耐火性多发性髓瘤 (RRMM) 患者进行了talquetamab的评估.
- 由于GPRC5D向和T细胞重定向,出现了一个独特的安全概况,需要特定的管理策略.
研究的目的:
- 描述talquetamab在RRMM患者中的安全概况.
- 概述与talquetamab相关的不良事件 (AE) 的管理策略.
- 评估AE的临床可控性及其对患者生活质量的影响.
主要方法:
- 第1阶段和第2阶段的MonumenTAL-1试验 (NCT03399799/NCT04634552) 的数据分析.
- 与GPRC5D相关的AEs和与T细胞重定向相关的AEs的表征.
- 对AE管理协议和结果的审查.
主要成果:
- 在RRMM患者中,整体应答率超过71%.
- 常见的GPRC5D相关的副作用包括皮肤病 (皮疹,指甲毒性) 和口腔毒性 (湿疹,口腔干燥).
- 细胞因子释放综合征 (CRS) 和神经毒性 (ICANS) 的发生率与其他T细胞重定向疗法一致;高度感染的发生率较少.
结论:
- 塔尔奎他马布表现出明显但在临床上可管理的安全性,主要是低级别的副作用.
- 建立了对AE的有效管理策略,包括皮肤,口腔,CRS和ICANS.
- 医疗保健提供者教育和患者支持对于在接受talquetamab的RRMM患者中维持生活质量和治疗坚持至关重要.
更多相关视频
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.4K
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
6.4K
相关概念视频
Pulmonary Tuberculosis V
177
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
177
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Tumor Immunotherapy
511
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
511
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)